

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology* 

Manuscript NO: 76517

Title: Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression

Provenance and peer review: Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

Reviewer's code: 03706467

**Position:** Peer Reviewer

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor, Postdoc

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2022-03-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-20 04:09

Reviewer performed review: 2022-03-20 05:50

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	[ ] Accept (High priority)       [ ] Accept (General priority)         [ Y] Minor revision       [ ] Major revision       [ ] Rejection
Re-review	[Y]Yes []No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

In the manuscript entitled "Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression" authors have tried to present an interesting phenomenon that COVID-19 infection caused alteration of gut microbiota may impact the progression of pancreatic cancer in patients via immune regulation. I have some minor comments to the text. The writing is poor. For example, a. "Additionally, we also proposed to explore the potential of modulating gut microbiota to create a favorable host environment to prevent both diseases, boost immune response, and reduce adverse prognostic outcomes by regulating the lung-gut-pancreases axis." b. "In addition, treatment evaluation of synergistic strategies such as dual or multiple agents and targeting multiple targets are needed. " Besides, to make this article more interesting, authors could try to reflect more of the clinical value, including its limitations.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology* 

Manuscript NO: 76517

Title: Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression

Provenance and peer review: Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

Reviewer's code: 00054672

**Position:** Editorial Board

Academic degree: FEBG, MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Croatia

Author's Country/Territory: United States

Manuscript submission date: 2022-03-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-20 02:09

Reviewer performed review: 2022-03-25 14:36

Review time: 5 Days and 12 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ Y] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[ ]Yes [Y]No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

This is a comprehensive review regarding pancreatic cancer and gut micobiota in the context of COVID-19. I have no major concerns regarding the content or structure of the text. However the manuscript needs English editing.